Latest News and Press Releases

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML – ...

Completion of patient dosing in the registrational Phase 2 clinical trial for 64Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate...

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics,...

Alkeus Pharmaceuticals announces first patient dosed in pivotal global Phase 3 NORTHSTAR Study of oral gildeuretinol in Stargardt disease.

OMN6: First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept

First-in-class oral ERAP1 inhibitor shows 13–36% ORR across 6 solid tumor types in anti-PD-1 resistant patients

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis At Week 44, both the 25 mg and 50 mg once-daily obefazimod...

Abivax annonce des résultats majeurs de l’essai de maintenance de phase 3 ABTECT évaluant l’obéfazimod dans le traitement de la rectocolite hémorragique active modérée à sévère À la semaine 44, les...

Dr Falk and Renexxion commit to late-stage development following naronapride’s positive P2b results in gastroparesis, a disease with high unmet need.

Nouscom receives FDA Fast Track Designation for NOUS-209, advancing development of its cancer-prevention immunotherapy for Lynch Syndrome carriers.